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Strengths and limitations of this study
 ► Novel pharmacy research network allows for effec-
tive recruitment of herpes simplex labialis sufferers 
that most often access treatment in the community.
 ► Single- dose intervention eliminates treatment com-
pliance issues.
 ► Digital data collection minimises study burden for 
investigators and participants and ensures real- 
time, accurate data collection.
 ► Self- report measures for lesion progression verified 
by pharmacy visit 2.
 ► Self- reported outcomes for days in- between phar-
macy visits are subjective and may overestimate 
or underestimate lesion progression or symptom 
severity.
ABSTRACT
Introduction Herpes simplex labialis (HSL) is a common 
infection that can cause painful lesions on the oral 
mucosa, commonly referred to as cold sores. Current 
biomedical treatments include topical aciclovir, which 
reduces the episode duration by an average of 0.5 days. 
This study will examine the efficacy and tolerability of 
an over- the- counter topical treatment, Dynamiclear in 
reducing duration and severity of HSL episodes.
Methods and analysis This prospective, randomised, 
double- blind, placebo- controlled, multi- centre trial will 
recruit a minimum of 292 adult participants across 
Australia and New Zealand who present with a cold sore 
within 48 hours of onset. They will be randomly allocated 
in a 2:1 ratio to receive either topical Dynamiclear 
(active) or placebo. Dynamiclear’s active ingredients are 
Hypericum perforatum, Calendula Officinalis and copper 
sulfate. A single topical treatment of active or placebo 
will be applied by a pharmacy- based investigator, and 
participants will be provided with a viral swab kit to 
confirm presence of herpes virus 1 or 2 from ulcerated 
lesions. Participants will receive reminders by email and/
or SMS to complete an online daily diary assessing their 
cold sore lesion using a visual guide, and recording other 
symptoms on numeric scales until healed. The primary 
outcome variable is median duration of HSL episode in 
days (participant evaluated) from presentation to return 
to normal skin. Secondary outcomes include severity 
of lesion pain, itching, burning and tingling during the 
symptomatic phase and proportion of lesions progressing 
to ulceration.
Ethics and dissemination Australian ethics approval 
from Western Sydney University Human Research Ethics 
Committee, ref: H12776. New Zealand Ethics approval 
from The Health and Disability Ethics Committees (HDEC) 
ref: 18/CEN/151. Results will be published in a peer- 
reviewed academic journal, presented at academic 
meetings and reported to participants
Trial registration numbers Australia and New Zealand 
Clinical Trials Registry (ACTRN12618000890235); 
Universal Trial Number (UTN) (U1111-1233-2426).
InTRoduCTIon
Herpes simplex labialis
Herpes simplex labialis (HSL) is a common 
recurring infection of the labial or perioral 
skin caused by herpes simplex virus (HSV), 
also known as cold sores. The majority of 
cases are caused by HSV-1. Seroprevalence 
studies indicate that 60%–90% of adults 
are infected with HSV-1 and that HSV is the 
fastest growing infectious disease in the world 
with 500 000 new cases reported each year.1 
Approximately 20%–40% of the population 
experiences recurrent outbreaks of HSL. 
The frequency of outbreaks ranges from 
rare episodes every 5–10 years, to monthly or 
more frequent outbreaks.2
Symptoms of active infection include 
prodromal numbness and tingling around 
the affected area, before progression to 
erythema, itching, burning, pain in the area 
and ulcerated lesions. Disease episodes are 
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generally mild and self- limiting1; however, the symptoms 
are uncomfortable and often more importantly aestheti-
cally unpleasant and noticeable to the general public.
Primary herpes simplex infection is most often asymp-
tomatic, however can manifest significant morbidity 
including general anorexia and malaise, fever, local 
lymphadenopathy, gingivostomatitis and significant 
ulcerative lesions; these symptoms may persist for up to 
3 weeks.3 Following the initial infection, the virus estab-
lishes a chronic, latent and lifelong infection in sensory 
nerve ganglia, predominantly the trigeminal ganglion.4 
At a later date, the virus may be reactivated and travel 
back to the oral mucosa, perioral skin and/or labial 
surfaces, where it replicates, producing a clinical episode 
of recurrent herpes labialis. Viral reactivation usually 
occurs due to stress on the immune system. Triggers 
include exposure to ultraviolet (UV) light exposure,5 and 
viral infections such as colds and flu.6 Recurrent episodes 
are shorter than the initial episode, with the virus often 
cleared within 3 days or less, due to the previously acquired 
immune response.1 This immune response contributes to 
rapid control of recurrent HSL disease episodes but may 
also be responsible for clinical signs and symptoms such 
as pain, redness and swelling that can persist for up to 
a week or longer, even after the virus can no longer be 
isolated.2
Current standard treatments for HSL
Oral and topical aciclovir preparations are used as the 
current standard of care for the treatment of HSV. Oral 
antiviral medications such as aciclovir, valaciclovir, famci-
clovir limit replication of the HSV by inhibiting viral 
DNA polymerase, and can shorten the time to healing 
from half a day to just over 2 days compared with placebo 
depending on the type of medication and dosage used.1 
Adverse events are generally mild and similar to placebo.7 8
Topical treatment with aciclovir and other antivirals 
have also shown modest clinical benefit, reducing average 
healing time by around half a day compared with vehicle 
control.1 9 Topical aciclovir demands good compliance, 
requiring daily application but is generally well tolerated, 
with an adverse event rate similar to vehicle control.9
Composition of dynamiclear
Dynamiclear (Sci- chem International) contains three 
active ingredients traditionally used to help treat inflamed 
or infected skin: Hypericum perforatum extract, Calendula 
officinalis extract and copper sulfate pentahydrate.
H. perforatum, or St. John’s Wort, has demonstrated 
antiviral activities against enveloped viruses such as HSV 
and HIV. The active constituent, hypericin, reduces viral 
replication, through inhibition of new virion budding, 
prevention of viral uncoating and inhibition of protein 
kinase activity.10 Hypericin has also been found to inhibit 
protein kinase C gamma and epsilon, which are proteins 
associated with the development of neuropathic pain.10 
For treatment of HSL skin lesions, H. perforatum is likely 
to be effective for topical application only as ingestion 
can cause photosensitivity, which may promote HSL 
reactivation.11
C. officinalis has been traditionally used for minor 
skin infections and inflammation.12 Recent studies have 
found calendula to be effective in reducing the time to 
healing in previously non- healing venous leg ulcers.13 
This is likely to occur through the upregulation of genes 
controlling connective tissue growth factor and α-smooth 
muscle actin14 and the proliferation and migration of 
fibroblasts.15 C. officinalis may therefore reduce the time 
to wound healing in HSL lesions that progress to an ulcer-
ative phase.
Copper sulfate is a naturally occurring mineral which has 
demonstrable antiviral activity. Rather than suppressing 
viral replication, copper ions render the viral DNA non- 
viable for further replication. HSV has been shown to 
exhibit sensitivity to low concentrations of copper, and in 
vitro research has shown evidence for copper- mediated 
inactivation of HSV.16
A non- blinded, active comparator randomised 
controlled trial17 of a previous version of Dynamiclear 
(without C. officinalis) demonstrated lower odds of having 
pain, redness or progressing to the vesicle stage compared 
with topical 5% aciclovir in the treatment of orolabial and 
genital herpes simplex episodes. However, interpretation 
of these results is limited due to the inclusion of multiple 




To evaluate the efficacy of one topical dose of Dynami-
clear in the treatment of HSL by a reduction in episode 
duration.
Secondary objectives
1. To assess the effect of Dynamiclear on the progression 
to ulcerative v non- ulcerative lesions.
2. To assess the effect of Dynamiclear on the duration of 
wound healing.
3. To assess the effect of Dynamiclear on pain, tender-
ness, tingling and itching during the disease course of 
HSL.
4. To assess patient satisfaction of the Dynamiclear 
product.
Hypothesis
A single topical application of Dynamiclear has greater 
efficacy than placebo on the severity and duration of HSL
METHodS And AnALySIS
Study design
A prospective, randomised controlled, double- blind, 
multi- site trial to evaluate the efficacy of a single dose 
of topically applied Dynamiclear versus placebo on the 
duration and severity of HSL.
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Box 1 Inclusion and exclusion criteria
Inclusion criteria
 ► Age 18–65 years.
 ► Onset of prodromal or clinical symptoms of HSL in the past 48 hours.
 ► Previous clinical history of HSL with at least three prior episodes 
of HSL.
 ► Primary lesion within 1 cm of the lip.
 ► Willing to provide informed consent and adhere to study protocol.
 ► Has internet (either by mobile or computer) to complete online forms.
Exclusion criteria
 ► History of immunodeficiency, immunosuppression or autoimmune 
disorder.
 ► Current infection not related to the study condition—for example, 
infections such as cold or influenza.
 ► Use of other antiviral, anti- inflammatory or steroid medications 
during or within 2 weeks prior to the treatment period.
 ► Use of other topical agents (including cosmetics, lip balms, sun-
screens) or cosmetic procedures (such as chemical peels or micro-
dermabrasion) on the prodromal or lesion area during the treatment 
period.
 ► Mechanical disruption (eg, scrubbing lancing or shaving) of the pro-
dromal or lesion area during the treatment period.
 ► Pregnancy, lactation or planning to become pregnant in the follow-
ing 14 days.
 ► Participation in another clinical trial within the previous 30 days.
HSL, herpes simplex labialis.
Sample size calculation
The sample size needed to demonstrate statistically and 
clinically significant efficacy was determined using the 
hypothesis that the mean episode duration in the treat-
ment group will be 5.0 days, compared with 6.0 days 
in the placebo group. This is based on the review of 
previous studies of aciclovir versus placebo by Harmen-
berg et al1 and a clinically significant difference of 1 day 
in episode duration. Given an alpha of 0.05, power of 
80% and an allocation ratio of 2:1 for treatment to 
placebo, 149 participants are required in the treatment 
group and 75 in the placebo group (224 in total). A 
recent study of kanuka honey versus aciclovir to treat 
cold sores, using the New Zealand Pharmacy based 
Research Network (PRN) for recruitment, reported 
an 11% dropout rate. However, because our study is 
placebo- controlled, we anticipate a higher dropout 
rate. Allowing for a 30% dropout rate, 292 participants 
are required: 194 in the treatment group and 98 in 
the control group. This sample size will also power the 
study to detect a moderate effect size on the secondary 
outcome measures (Cohen’s d=0.4).
Participants
A total of 292 participants aged 18–65 presenting to 
participating pharmacies within 48 hours of onset of 
prodromal symptoms of HSL and who report at least 
three prior episodes of HSL will be recruited. Inclusion 
and exclusion criteria are presented in box 1.
A PRN in both New Zealand and Sydney, Australia 
will be used to register sites for primary recruitment, 
screening and assessment.
Study centres: 10–15 pharmacies in Sydney, Australia, 
and 20–25 pharmacies in New Zealand.
Patient and public involvement (PPI)
There were no funds or time allocated for PPI so we were 
unable to involve patients in the study design. We will 
invite patients at the conclusion of the study to provide 
feedback on the burden of the intervention, and patients 
will be involved in developing the dissemination strate-
gies for our findings.
Recruitment and selection
Four parallel recruitment pathways are planned in this 
study. First, social media will be used to advise participants 
of the trial, and refer them to a web page which outlines 
the inclusion and exclusion criteria and encourage them 
to present at participating pharmacies within 48 hours of 
the onset of a cold sore. Second, the New Zealand arm of 
the PRN has recently completed a different HSL study.18 
The 920 participants who joined that study and consented 
to being contacted for further studies will be sent an email 
informing them of this study. Third, all participating PRN 
pharmacies will have promotional material in their phar-
macies and individuals presenting to these pharmacies 
with a cold sore recurrence within the past 48 hours will 
be invited to enrol in the study. Fourth, TrialFacts, a paid 
recruitment service, will be used to advertise and screen 
for potential participants. Recruitment will begin in June 
2019.
Regardless of recruitment pathway, on presentation at 
a participating pharmacy, potential participants will be 
screened and those eligible will be consented by phar-
macists and pharmacy technicians. Recruitment staff will 
ensure that each participant is fully informed about the 
nature and objectives of the study and possible risks asso-
ciated with participation.
Randomisation
After providing informed consent and satisfying the eligi-
bility criteria, participants will be randomised in a 2:1 
ratio to receive either active treatment with Dynamiclear 
(n=194) or the placebo- controlled group (n=98) using the 
Castor EDC platform.19 Randomisation will be performed 
using the Castor EDC platform by a researcher indepen-
dent of the study team. To maintain pharmacist blinding 
when using a 2:1 ratio, boxes containing the intervention 
are prerandomised, and pharmacists are provided with a 
box code rather than a group allocation. A 2:1 ratio in 
favour of the active intervention was chosen to maximise 
recruitment rates as potential participants are actively 
seeking treatment when attending the pharmacy. Thus, a 
greater chance of being allocated active treatment is likely 
to increase recruitment and retention rates. Permuted 
block randomisation, with a block size of 6 or 9 will be 
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Box 2 Composition of interventional product 
(dynamiclear) and placebo
A. Composition of interventional product (dynamiclear)
Active ingredients
 ► Calendula officinalis 1:2 liquid extract, 0.05 %w/w.
 ► Hypericum perforatum 1:2 liquid extract, 0.05 %w/w.
 ► Copper sulfate pentahydrate, 6.4 %w/w.
Excipient ingredients:
 ► Aloe vera
 ► Glycerol
 ► Vitamin E (tocopheryl acetate)
 ► Hydroxyethyl cellulose
 ► Polysorbate 80
 ► Purified water
B. Composition of placebo
Masking ingredients:
 ► Blue dye
 ► Yellow dye
Excipient ingredients:
 ► Aloe barbedensis
 ► Glycerin
 ► Vitamin E (tocopheryl acetate)
 ► Hydroxyethyl cellulose
 ► Polysorbate 80
 ► Purified water
 ► Sodium benzoate
 ► Citric acid anydrous (pH adjustor)
undertaken for each pharmacy to ensure that no patterns 
or imbalances emerge in group allocation between sites.
Blinding
All pharmacy staff, study team, participants and data 
analysts are blind to the group allocation. Unblinding 
will be permitted for either Dr Ee or Dr Semprini, or 
any other medical monitor, if serious adverse events are 
reported.
Study interventions
Interventional treatment is applied once only during 
pharmacy visit 1. Each participant will be allocated one 
vial of Dynamiclear or a placebo that matches Dynami-
clear in colour, viscosity, taste and smell. The active and 
placebo vials are presented in identical packaging. The 
intervention or placebo will be applied via a cotton- tipped 
applicator which delivers 0.7 mL to the affected area. This 
will be done either by the trained investigator or by the 
participant in view of the investigator, and the vial and 
packaging disposed of immediately. The moistened appli-
cator will be applied for a minimum of 30 s, directly on 
the HSL lesion. No investigational product or packaging 
will leave the pharmacy site for any reason. Box 2 outlines 
the composition of both the interventional product and 
placebo.
data capture and monitoring
All data will be captured electronically via the secure 
electronic data capture platform CastorEDC.19 Each 
pharmacy will be provided with an iPad (Apple Inc) 
which will be used to collect all data during each face to 
face clinical visit. Signed consent forms will be digitally 
captured and uploaded directly onto the EDC platform.
Each participant will attend two clinical visits at PRN 
pharmacies. Visit 1 will be within 48 hours of symptom 
onset and will include initial clinical assessment and a 
single application of either the intervention or placebo 
in the presence of trained pharmacy staff. Visit 2 will be 
triggered when the participant indicates via their online 
symptom diary that they have returned to normal skin 
(stage 7). This visit will involve confirmation of healing by 
pharmacists and checking for adverse events.
Participants will report symptoms and healing progres-
sion in an online daily diary (hosted on Castor EDC) 
which researchers will monitor for reports of adverse side 
effects. These diaries will also be used to monitor patient 
adherence to study requirements.
Participants will receive a follow- up phone call by 
a member of the research team 2 weeks after their 
final pharmacy visit to monitor any adverse events post 
treatment.
All data will be securely held on the study team data-
base, accessible only by authorised investigators for the 
purposes of monitoring. The final dataset will be acces-
sible by the coordinating investigators and each locality 
will retain on- site access to digital copies of source docu-
mentations with paper copies stored in secure archives.
Any changes to the study protocol are provided to the 
Human Research Ethics Comittee (HREC) and Health 
and Disability Ethics Committees as per protocol, trial 
registries will be updated and updated copies provided 
to trial sites. A copy of the consent form is included as 
online supplementary file 1.
Clinical assessments and patient surveys will be 
completed using Castor clinical trials management soft-
ware. All the pre- specified outcome measures are outlined 
in box 3.
A systematic review by Harmenberg et al,1 a recent mini 
review by Hull13 and the most recent Cochrane system-
atic review protocol20 outline a number of important 
outcome measures which informed the choices in box 3. 
Median duration of the episode, as defined by the time 
to healing either by the loss of the hard crust in partic-
ipants with ulcerative lesions or the time to normal skin 
(complete epithelialisation) in those with aborted lesions, 
either participant or clinician reported is the most 
common clinically relevant outcome measure. However, 
both Harmenberg and Hull argue that using duration 
of healing alone may miss important clinical effects, for 
example, if lesion duration is less but the size of the lesion 
is greater this may not indicate an improvement in the 
condition from the patient’s perspective. The ulcerative 
stage of the lesion is the most painful and cosmetically 
bothersome stage of the lesion. Given the difference in 
disease severity between ulcerative and non- ulcerative 
lesions, the proportion of these lesions is commonly used 
as another important outcome measure, which may be 
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Box 3 outcome measures
Primary outcome measure:
 ► Median episode duration in days (participant evaluated).
Secondary outcome measures:
 ► Median episode duration in days (investigator evaluated).
 ► Proportion (%) of lesions progressing to ulceration.
 ► Median duration from wound development (stage 4) to healing 
(stage 7) in days (participant evaluated).
 ► NRS for pain, tenderness, tingling and itching during the symptom-
atic phase.
 ► Proportion (%) of cases of HSV confirmed via swabs.
 ► Adverse event rate.
 ► Patient satisfaction and acceptability.
HSV, herpes simplex virus; NRS, numeric rating scale.
of greater concern to HSL sufferers than a small reduc-
tion of episode duration often seen in topical treatment. 
Harmenberg compellingly argues that an important 
marker in placebo- controlled trials is the proportion of 
participants that develop ulcerative lesions despite use 
of the study medication, as a reduction in progression to 
ulceration is of significant clinical benefit to sufferers.1 
Indeed a common feature of antiviral therapies is not a 
significant reduction in overall duration, but a shortening 
of the duration of time of wound healing,21 which is still a 
very important clinical benefit.
Finally, the painful symptoms of burning, tingling and 
itching are commonly found in participants with HSL, 
and are usually bothersome and therefore a reduction 
in either severity or duration of these is an important 
patient- centric outcome.
Participant evaluated lesion stage
Participants will be provided with photo images as well as 
descriptions for each lesion stage via an online web form. 
We have used this lesion staging system in our previous 
trial.22 Participants will be asked to grade the lesion 
once per day, on waking, until return to normal skin 
occurs (stage 7) or until 14 days from pharmacy visit 1. 
A reminder SMS and/or email will be sent each morning 
with an embedded link to the web form. This grading 
will be submitted via an online web form. When a partic-
ipant grades their lesion having resolved and the area 
has returned to normal skin (stage 7) via the online form 
they will be contacted to attend for assessment to their 
nearest study site within 24 hours by phone and email by 
the research assistant.
Investigator-evaluated lesion stage
Study participants will have their lesion stage graded by 
trained pharmacists and pharmacy technicians at two 
stages: (1) on the initial clinical visit for enrolment and 
(2) once participants indicate that healing has occurred 
they will have their lesion stage confirmed by clinicians 
at a study site within 24 hours (see exceptions below). 
Investigators will be provided with photo images as well 
as descriptions for each lesion stage, identical to those 
provided to the participant. They will assess this inde-
pendently of the participant’s own grading.
Episode duration
The episode duration will be defined as follows: if no 
vesicle formed then duration was from the initiation of 
treatment to the return to normal skin with cessation of 
signs or symptoms (aborted lesion); if a vesicle formed, 
the duration of episode was measured from the initiation 
of treatment to the loss of hard crust (stage 6: residual 
erythema could be present after loss of hard crust). Dura-
tion of wound healing will be determined by the time 
between the development of an ulcer (stage 4) to return 
to normal skin (stage 7). This will provide an estimate of 
the interventions effect on the most cosmetically bother-
some and painful stage of the episode.
Participant-graded pain and other symptoms
Participants will grade lesion pain once per day on waking 
on a 0–10 numeric rating scale (NRS) from onset of symp-
toms until healing occurs, with 0 being no pain and 10 
the worse pain imaginable. Symptoms of burning, itching 
and tingling will be measured using a separate 4- point 
ordinal scale for each symptom as follows: 0=not present, 
1=mild, 2=moderate and 3=severe. This score will be 
submitted via the online web portal along with lesion 
stage assessment.
Participant satisfaction questionnaire
At tpharmacy visit 2, participants will be asked to rate 
their satisfaction with the treatment given using a Likert 
scale. Questions will include the likelihood of recommen-
dation of the intervention to family and friends, interest 
in using the intervention again for future cold sores and 
ranking the intervention relative to other previous treat-
ments they have used (if any) for cold sores.
Laboratory assessments
For confirmation of HSV infection, participants will use 
the swab kits provided at the initial clinical consultation to 
take swabs of lesions that reach an ulcerative stage (stage 
4) and do not have evidence of crusting (to avoid inter-
ference with the healing process). Samples will be taken 
by participants at home using a supplied dry swab that will 
be gently rubbed on the lesion in a circular motion for 5 s, 
then placed in a sterile outer tube, stored in their fridge 
(below 8°C) and shipped for viral culture to a central 
laboratory within 72 hours from sampling by courier. The 
presence of HSV will be diagnosed by the appearance of 
typical cytopathic effects. Isolates will be typed (HSV-1 
and HSV-2) by immunofluorescent antibody technique. 
Those participants who have non- ulcerative (or aborted) 
lesions will not be asked to provide swabs as removing 
fluid can delay healing.
Adverse events
Adverse events will be monitored via the daily online diary, 
during the study visit 2 and 2 weeks after pharmacy visit 2.
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Daily via online 
diary





2 weeks after 
site visit 2
Written informed consent X
Inclusion and exclusion X
Medical history X
Randomisation X
Treatment or placebo applied X
First lesion occurs X
Clinical confirmation of lesion stage X X
Participant online diary—lesion stage, pain, 
stage and other symptoms
  X




Adverse events recorded   X X X
Other treatments   X
HSV, herpes simplex virus.
Adverse events will be graded using the NCI Common 
Terminology Criteria for Adverse Events Version 4.0 and 
reported to the sponsor and HREC. After the end of study 
and locking of the study database, all adverse events will be 
summarised.
data monitoring and stopping guidelines
Data will be monitored for completeness, plausibility and 
consistency to ensure the integrity and completeness of 
the dataset. Any queries will be resolved by the chief inves-
tigator or delegated member of the study team. Adverse 
events will be regularly monitored via the online daily 
diary, as well as at the pharmacy visit 2 and at the conclu-
sion of the 2 week post trial period. Any serious adverse 
events will trigger an alert to the chief investigator.
Study timeline
The expected duration of the data collection phase of this 
study will be 12 months, with 14 time points where data will 
be collected. The schedule of events is outlined in table 1.
Statistical analysis of outcome data
Efficacy analyses will be performed for both the intent- 
to- treat population (all participants) and per- protocol 
population (excluding participants with missing data). 
The analysis for the primary outcome of median dura-
tion of episode as reported by the participant, from the 
stage at presentation to the clinical site until healing and 
for the secondary outcomes of the median investigator 
rated duration, and median duration of wound develop-
ment will all be analysed using a Mann- Whitney U test. 
Differences between groups in proportion of lesions 
progressing to ulceration, proportion of confirmed HSV, 
adverse events rates and participant satisfaction rates will 
be compared using χ² tests.
Differences in NRS ratings for pain, tenderness, tingling 
and itching will be analysed using linear mixed model 
analysis of variance with group and time as fixed effects. 
In mixed model analysis subject will be used as a random 
effect. Secondary outcomes will include Cox proportional 
hazards for time to healing and time of wound duration 
and Kaplan- Meier survival plots. Multilevel analysis may 
be conducted with different factors including country, 
gender and number of previous episodes. Results will be 
documented with p- values and 95% CIs. Data will be anal-
ysed using SAS V9.4 and/or SPSS V.24 software.
Participant safety
The product has been listed as a listed medicine on the 
Australian Register of Therapeutic Goods (ARTG) (AUST 
L 241934).
The Australian Therapeutic Goods Administration 
(TGA) have approved the safety of all ingredients for use 
in complementary medicines in Australia. A detailed dose 
justification and safety profile with supporting literature 
for each of the components of Dynamiclear are detailed 
in Product Information provided by the Sponsor, Sci- 
Chem, in support of listing on the ARTG.
As the investigational product (Dynamiclear) is a low- 
risk product already approved by the TGA and available 
for purchase, a formal data monitoring committee will 
not be established in Australia or New Zealand. However, 
the nominated medical representatives for the study, Dr 
Carolyn Ee (a registered General Practitioner in Australia) 
and Dr Alex Semprini (a registered medical practitioner 
in New Zealand), will review safety on all adverse events. 
The Dynamiclear formulation is considered safe to apply 
topically at the dosages outlined; however, individual 
components may irritate the skin in sensitive individuals. 
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Copper sulfate, Calendula and Hypericum can all be irri-
tating to the skin and mucosa in some individuals.
Methods for adverse event recording and reporting 
include the daily online diary which asks participants 
to report any adverse events over the previous 24 hours. 
Adverse events are also recorded at site visit 2 by the phar-
macist and any post- trial events by a phone call 2 weeks 
following site visit 2. All participants will also be provided 
with a digital emergency contact card with details of 
whom to contact in the case of an emergency.
Post-trial care
After the trial has been completed and data analysis 
undertaken, participants will be advised of their group 
allocations and the study results. If the intervention is 
found to be effective, those in the placebo group will be 
offered one free treatment of the interventional product. 
All participants will be advised of the availability of the 
name of the product and its availability to purchase over- 
the- counter, if they wish to use it in future. Full indemnity 
insurance is in place for the study sponsor in the case of 
claims resulting from trial participation.
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cies will receive summarised results of the publication.
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